Najat Khan, Chief R&D Commercial Officer at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 76,987 shares at $5.52 ($425K) on 2025-08-18, disclosed to the SEC on 2025-08-19.
Open-market sale of $425k RXRX by Chief R&D Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.64 | 3,789 | $21K | 5.0% |
| 2 | $5.52 | 36,599 | $202K | 47.5% |
| 3 | $5.52 | 36,599 | $202K | 47.5% |
| Total | $5.53 avg | 76,987 | $425K | 100% |
| Filing → |
| RXRX | SELL | 2026-03-11 | $189K | — | Filing → |
| RXRX | SELL | 2025-12-29 | $1.1M | — | Filing → |